Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term management study of pimecrolimus cream 1% in pediatric mild to moderate atopic dermatitis
2017-001766-25Phase 4
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pimecrolimus in atopic dermatitis (AD), sponsored by Novartis. Primary endpoint: Number of days of TCS usage.
02
Drugs
pimecrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-001766-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001766-25.